The intracellular metabolism and cytostatic activity of the anticancer drug gemcitabine (2′,
2′-difluoro-2′-deoxycytidine; dFdC) was severely compromised in Mycoplasma hyorhinis …

Abstract Background Topoisomerase 2‐alpha (TOP2A) is an enzyme that controls topologic
changes in DNA during transcription and replication. ERCC1 is an enzyme that takes part in …

Most mycoplasmas are present as commensals, colonising the mucosa of our respiratory
and gastrointestinal tract. Experimental data suggest that the long-term association of certain …

Geometry optimization of gemcitabine was carried out by DFT with B3LYP/6-311++ G (d, p)
level in the gas phase. Chemical activity (electronegativity, electrophilicity, hardness …

Purpose The combination of cisplatin plus gemcitabine is active in metastatic breast cancer.
Carboplatin plus gemcitabine, widely used in ovarian and non–small-cell lung cancers, has …

In this work, a semimechanistic tumor growth-response model for gemcitabine in pancreatic
(administered as single agent) and ovarian (given as single agent and in combination with …

Gemcitabine (2′, 2′‐difluorodeoxycytidine; dFdC) is a deoxycytidine analog and is used
primarily against pancreatic cancer. The cytotoxicity of gemcitabine is due to the inhibition of …

Combined chemotherapy has drawn much attention for overcoming drug resistance and
improving outcomes during the treatment of advanced stages of cancer. In the present study …

Background: GEMCITABINE (2', 2'-difluoro-2'-deoxycytidine, an analogue of deoxycytidine)
is a relatively new drug with wide range of anti-cancer activity. In this study, radiosensitizing …

Abstract Starting from 5-iodo-2'-deoxyuridine, a series of 5-alkynyl-2'-deoxyuridines have
been synthesized and isolated via the palladium-catalyzed coupling followed by an …